Gefitinib

Tier C — Watch / trade

Gefitinib

AstraZeneca

Originator

2002

First approval

Expiry (public)

$0.65B ▲

Peak sales

Small molecule

Type

Targets：EGFR, EGFR 19del, EGFR L858R

Brand：Iressa

Indications (approved)：Non-small cell lung cancer

Regional status

Withdrawn

Approved

2009-06-24

China

Approved

2004-12-06

Japan

Approved

2002-07-05

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Gefitinib?

Approved indications include: Non-small cell lung cancer.

When does the Gefitinib patent expire?

No public expiry year is available for Gefitinib yet; this page updates once verified.

How do I get a quote for Gefitinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27